Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | DDX3X | O00571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21037205 | 0.79 | PDE10A (0.36) | PDE10ANOS3NOS1NOS2ESR1 | |
| SCHEMBL12702786 | 0.75 | GRM4 (0.33) | — | |
| SCHEMBL19386401 | 0.73 | MAPT (0.41) | PDE10ANOS3NOS1NOS2AKT1 | |
| SCHEMBL19386404 | 0.73 | GABRA1 (0.40) | PDE10AAKT1ESR1 | |
| SCHEMBL21037212 | 0.72 | NOS3 (0.39) | PDE10ANOS3NOS1NOS2ESR1 | |
| SCHEMBL7991401 | 0.72 | CYP1A2 (0.45) | PDE10A | |
| SCHEMBL3122540 | 0.70 | ATM (0.51) | PDE10ANOS3NOS1NOS2TLR7 | |
| SCHEMBL18417280 | 0.70 | GABRA1 (0.40) | ESR1 | |
| SCHEMBL24357972 | 0.69 | NPC1 (0.46) | PDE10A | |
| SCHEMBL21037206 | 0.68 | ABL1 (0.33) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | PDE10A 970/4885NOS3 243/4885NOS1 439/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | PDE10A 970/4885NOS3 243/4885NOS1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.